跳至主要内容
临床试验/NCT02548845
NCT02548845已完成不适用

An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA)

Otsuka Pharmaceutical Europe Ltd0 个研究点目标入组 70 人开始时间: 2015年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
70
主要终点
Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)

研究概览

简要总结

In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed. Since it is hypothesised that the adherence to the SEOM algorithm is not 100%, the current retrospective non-interventional study will investigate the perceived and actual adherence of participating centres to the SEOM algorithm and its impact on patient outcomes

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Provision of patient informed consent unless a) not required by local regulations, b) it would represent a non-reasonable effort or c) if the source patient is deceased or untraceable.
  • Female and/or male oncology patients aged 18 years and over
  • Patients who have experienced at least one occurrence of hyponatraemia secondary to the SIADH.

排除标准

  • A patient cannot take part in this study if participating in any clinical study in which the medicinal product aims to treat the causes or symptoms of hyponatraemia at the time of the hyponatraemia episode being documented in the current study.

结局指标

主要结局

Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)

时间窗: Participants will be followed for the duration of hospital stay, an expected average of 4 days (follow-up will stop after a maximum of 6 weeks)

Adherence to the algorithm will be evaluated using a pre-defined decision tree that will be provided in the electronic case report form (eCRF) and will be completed by the investigator

次要结局

  • Length of Hospitalisation (Measured From the Start of the Hyponatraemia Episode to Discharge) for Patients Who Were and Were Not Treated in Adherence With the Algorithm(Longitudinal (up to discharge or a maximum of 6 weeks after onset of hyponatremia episode))
  • Time to Initiation or Re-initiation of Chemotherapy (Since the Start of the Hyponatraemia Episode) in Patients Candidate for Chemotherapy Who Were and Were Not Treated in Adherence With the SEOM Algorithm.(Longitudinal (up to discharge or a maximum of 6 weeks after onset of hyponatremia episode))
  • Time to Sodium Level Improvement for Patients Who Were and Were Not Treated in Adherence With the SEOM Algorithm (Hours)(Longitudinal (up to discharge or a maximum of 6 weeks after onset of hyponatremia episode))
  • Time to Sodium Level Improvement for Patients Who Were and Were Not Treated in Adherence With the SEOM Algorithm (Days)(Longitudinal (up to discharge or a maximum of 6 weeks after onset of hyponatremia episode))

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

已完成
3 期
A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancerocally advanced and metastatic pancreatic cancerLocally advanced and metastatic pancreatic cancerCancer
ISRCTN43482138The University of Liverpool (UK)1,062
已完成
不适用
Immunomonitoring by virus-specific T-cells and evaluation as a prognostic marker for virus-induced diseases after solid organ transplantatioPaediatric kidney transplantationSurgerySurgical operation and other surgical procedures
ISRCTN89806912Medical School of Hannover (MHH) (Germany)64
已完成
不适用
A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of TreatmentMetastatic Colorectal Cancer
NCT06137170Bayer121
已完成
不适用
Effectiveness of PDSAFE to prevent falls among people with Parkinson’s diseaseTopic: Dementias and neurodegenerationSubtopic: Parkinson's DiseaseDisease: Parkinson's diseaseNervous System DiseasesParkinson disease
ISRCTN48152791Southampton University Hospitals NHS Trust (UK)474
已完成
4 期
Tetanus vaccine safety in patients taking anti-coagulants: can it be administered intramuscularly instead of subcutaneously, as usually recommended?Patients treated with oral anticoagulants for whom at least one dose of anti-tetanus vaccine was indicatedHaematological DisordersTetanus vaccine
ISRCTN69942081Department of Health of Galicia (Spain)234